The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.
B. I. Sikic
Research Funding - Human Genome Sciences
S. G. Eckhardt
Research Funding - Human Genome Sciences
G. Gallant
Employment or Leadership Position - Human Genome Sciences
Stock Ownership - Human Genome Sciences
H. A. Burris
No relevant relationships to disclose
D. R. Camidge
No relevant relationships to disclose
A. D. Colevas
No relevant relationships to disclose
S. F. Jones
No relevant relationships to disclose
W. A. Messersmith
No relevant relationships to disclose
H. A. Wakelee
No relevant relationships to disclose
H. Li
Employment or Leadership Position - Human Genome Sciences
Stock Ownership - Human Genome Sciences
P. G. Kaminker
Employment or Leadership Position - Human Genome Sciences
Stock Ownership - Human Genome Sciences
S. Morris
Employment or Leadership Position - Aegera Therapeutics
J. R. Infante
Consultant or Advisory Role - Novartis